{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:48:41Z","timestamp":1775695721736,"version":"3.50.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.msard.2017.09.015","type":"journal-article","created":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T14:45:26Z","timestamp":1506350726000},"page":"144-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Diagnosis and management of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Iran: A consensus guideline and recommendations"],"prefix":"10.1016","volume":"18","author":[{"given":"Mohammad Ali","family":"Sahraian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdorreza Naser","family":"Moghadasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir Reza","family":"Azimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasrin","family":"Asgari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahimeh","family":"H. Akhoundi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roya","family":"Abolfazli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shekoofeh","family":"Alaie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fereshteh","family":"Ashtari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hormoz","family":"Ayromlou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Mohammad","family":"Baghbanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nahid Beladi","family":"Moghadam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farzad","family":"Fatehi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Foroughipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamidreza Ghalyanchi","family":"Langroodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nastaran","family":"Majdinasab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Nickseresht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbas","family":"Nourian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vahid","family":"Shaygannejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid Reza","family":"Torabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2017.09.015_bib1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: steroids alone versus Steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2017.09.015_bib2","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00415-016-8188-y","article-title":"Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study","volume":"263","author":"Annovazzi","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2017.09.015_bib3","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1600-0404.2010.01416.x","article-title":"Neuromyelitis optica (NMO)--an autoimmune disease of the central nervous system (CNS)","volume":"123","author":"Asgari","year":"2011","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2017.09.015_bib4","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00415-009-5171-x","article-title":"Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution","volume":"256","author":"Bizzoco","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2017.09.015_bib5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/1352458508100837","article-title":"Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder","volume":"15","author":"Bonnan","year":"2009","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2017.09.015_bib6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10072-007-0823-z","article-title":"Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease)","volume":"28","author":"Capobianco","year":"2007","journal-title":"Neurol. Sci.: Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol."},{"key":"10.1016\/j.msard.2017.09.015_bib7","series-title":"Euromyelitis Optica. Current Treatment Options in Neurology","first-page":"244","volume":"12","author":"Carroll","year":"2010"},{"key":"10.1016\/j.msard.2017.09.015_bib8","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/1756285616632653","article-title":"An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica","volume":"9","author":"Collongues","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2017.09.015_bib9","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2017.09.015_bib10","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2017.09.015_bib11","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1352458513495938","article-title":"Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2017.09.015_bib12","first-page":"455","article-title":"Glucocorticoid treatment of multiple sclerosis","volume":"122","author":"Goodin","year":"2014"},{"key":"10.1016\/j.msard.2017.09.015_bib13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2217\/pgs.09.155","article-title":"Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications?","volume":"11","author":"Higgs","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.msard.2017.09.015_bib14","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","article-title":"Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder","volume":"71","author":"Huh","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2017.09.015_bib15","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/ana.21753","article-title":"\u201cCloud\u2010like enhancement\u201d is a magnetic resonance imaging abnormality specific to neuromyelitis optica","volume":"66","author":"Ito","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2017.09.015_bib16","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2017.09.015_bib17","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bpa.12084","article-title":"Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature","volume":"23","author":"Jarius","year":"2013","journal-title":"Brain Pathol."},{"key":"10.1016\/j.msard.2017.09.015_bib18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1742-2094-7-52","article-title":"Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance","volume":"7","author":"Jarius","year":"2010","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.msard.2017.09.015_bib19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jns.2012.06.002","article-title":"Testing for antibodies to human aquaporin-4 by ELISA: sensitivity, specificity, and direct comparison with immunohistochemistry","volume":"320","author":"Jarius","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2017.09.015_bib20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.msard.2017.09.015_bib21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1352458515587752","article-title":"Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints","volume":"22","author":"Jeong","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2017.09.015_bib22","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00415-015-7952-8","article-title":"Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO\/MS overlap syndromes","volume":"263","author":"Jurynczyk","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2017.09.015_bib23","article-title":"Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine","author":"Kandiel","year":"2005","journal-title":"BMJ J."},{"key":"10.1016\/j.msard.2017.09.015_bib24","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1212\/CON.0000000000000337","article-title":"Neuromyelitis optica spectrum disorders","volume":"22","author":"Katz Sand","year":"2016","journal-title":"Continuum"},{"key":"10.1016\/j.msard.2017.09.015_bib25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1212\/WNL.58.1.143","article-title":"Plasma exchange for severe attacks of CNS demyelination: predictors of response","volume":"58","author":"Keegan","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2017.09.015_bib26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jns.2010.12.001","article-title":"Brain abnormalities in neuromyelitis optica","volume":"302","author":"Kim","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2017.09.015_bib27","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1177\/1352458512441271","article-title":"Central nervous system aquaporin-4 autoimmunity presenting with an isolated cerebral abnormality","volume":"18","author":"Kim","year":"2012","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2017.09.015_bib28","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.msard.2017.09.015_bib29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jns.2014.01.035","article-title":"Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab","volume":"339","author":"Kitley","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2017.09.015_bib30","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1212\/01.wnl.0000345066.57745.50","article-title":"NMO-IgG detected in CSF in seronegative neuromyelitis optica","volume":"72","author":"Klawiter","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2017.09.015_bib31","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2017.09.015_bib32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4161\/mabs.3.2.14239","article-title":"Monoclonal antibodies in neuro-oncology: getting past the blood-brain barrier","volume":"3","author":"Lampson","year":"2011","journal-title":"mAbs"},{"key":"10.1016\/j.msard.2017.09.015_bib33","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1212\/WNL.0b013e3181b879be","article-title":"Plasma exchange for acute attacks of CNS demyelination: predictors of improvement at 6 months","volume":"73","author":"Llufriu","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2017.09.015_bib34","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/archneurol.2011.34","article-title":"Beneficial plasma exchange response in central nervous system inflammatory demyelination","volume":"68","author":"Magana","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2017.09.015_bib35","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","article-title":"Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine","volume":"51","author":"Mandler","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2017.09.015_bib36","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1212\/WNL.0b013e318211c379","article-title":"CSF complements serum for evaluating paraneoplastic antibodies and NMO-IgG","volume":"76","author":"McKeon","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2017.09.015_bib37","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2017.09.015_bib38","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ophtha.2006.06.060","article-title":"Natural history of the visual impairment of relapsing neuromyelitis optica","volume":"114","author":"Merle","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.msard.2017.09.015_bib39","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2017.09.015_bib40","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/jnnp.2008.150698","article-title":"Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker","volume":"80","author":"Misu","year":"2009","journal-title":"J. Neurol., Neurosurg., Psychiatry"},{"key":"10.1016\/j.msard.2017.09.015_bib41","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1471-4159.2011.07562.x","article-title":"Proteasomal degradation of tyrosine hydroxylase and neurodegeneration","volume":"120","author":"Nakashima","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.msard.2017.09.015_bib42","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1212\/WNL.50.6.1833","article-title":"Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study","volume":"50","author":"Oliveri","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2017.09.015_bib43","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.4103\/0972-2327.164816","article-title":"Neuromyelitis optica spectrum disorders: an update","volume":"18","author":"Pandit","year":"2015","journal-title":"Ann. Indian Acad. Neurol."},{"key":"10.1016\/j.msard.2017.09.015_bib44","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.4103\/0972-2327.164816","article-title":"Neuromyelitis optica spectrum disorders: an update","volume":"18","author":"Pandit","year":"2015","journal-title":"Ann. Indian Acad. Neurol."},{"key":"10.1016\/j.msard.2017.09.015_bib45","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/nyas.12794","article-title":"Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later","volume":"1366","author":"Pittock","year":"2016","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.msard.2017.09.015_bib46","doi-asserted-by":"crossref","DOI":"10.1001\/archneur.63.3.390","article-title":"Brain abnormalities in neuromyelitis optica","author":"Pittock","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2017.09.015_bib47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jneuroim.2015.03.016","article-title":"The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy","volume":"282","author":"Quan","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2017.09.015_bib48","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1468-1331.2009.02928.x","article-title":"Relapsing neuromyelitis optica: demographic and clinical features in Iranian patients","volume":"17","author":"Sahraian","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2017.09.015_bib49","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ncl.2012.09.010","article-title":"Neuromyelitis optica: clinical manifestations and neuroimaging features","volume":"31","author":"Sahraian","year":"2013","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.msard.2017.09.015_bib50","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13256-015-0613-9","article-title":"Neuromyelitis optica with linear enhancement of corpus callosum in brain magnetic resonance imaging with contrast: a case report","volume":"9","author":"Sahraian","year":"2015","journal-title":"J. Med. Case Rep."},{"key":"10.1016\/j.msard.2017.09.015_bib51","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.neurol.2016.03.003","article-title":"Neuromyelitis optica spectrum disorder (NMOSD): a new concept","volume":"172","author":"de Seze","year":"2016","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.msard.2017.09.015_bib52","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1191\/1352458505ms1190oa","article-title":"The mechanism of action of methylprednisolone in the treatment of multiple sclerosis","volume":"11","author":"Sloka","year":"2005","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2017.09.015_bib53","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/WNO.0b013e318283c3ed","article-title":"Distinguishing optic neuritis in neuromyelitis optica spectrum disease from multiple sclerosis: a novel magnetic resonance imaging scoring system","volume":"33","author":"Storoni","year":"2013","journal-title":"J. Neuro-Ophthalmol."},{"key":"10.1016\/j.msard.2017.09.015_bib54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2015.02.012","article-title":"Analysis of the treatment of neuromyelitis optica","volume":"351","author":"Torres","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2017.09.015_bib55","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jocn.2010.05.030","article-title":"The rescue effect of plasma exchange for neuromyelitis optica","volume":"18","author":"Wang","year":"2011","journal-title":"J. Clin. Neurosci.: Off. J. Neurosurg. Soc. Australas."},{"key":"10.1016\/j.msard.2017.09.015_bib56","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.msard.2017.09.015_bib57","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2017.09.015_bib58","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2017.09.015_bib59","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2017.09.015_bib60","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2017.09.015_bib61","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1177\/1352458515617248","article-title":"Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica","volume":"22","author":"Yamasaki","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2017.09.015_bib62","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.msard.2016.03.004","article-title":"Fingolimod-induced leukoencephalopathy in a patient with neuromyelitis optica spectrum disorder","volume":"7","author":"Yoshii","year":"2016","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034817302183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034817302183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:40:39Z","timestamp":1761900039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034817302183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":62,"alternative-id":["S2211034817302183"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2017.09.015","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and management of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Iran: A consensus guideline and recommendations","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2017.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}